Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive...
Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive...
科亞治療公司強調新任首席執行官下的戰略願景，包括2025年的關鍵里程碑，包括與雷迪博士合作進行ALS試驗，價值高達7千萬美元，圍繞帕金森病和自身免疫疾病的新興機會，並聚焦非稀釋性...
Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive Funding To Advance Treg-Enhancing Biologics For Neurodegenerative And Autoimmune Diseases
Coya Therapeutics在新CEO的領導下，突出戰略願景，其中包括2025年關鍵里程碑，包括與Dr. Reddy's合作的ALS試驗，價值高達70000萬美元，深入挖掘帕金森症和自身免疫疾病的新機遇，並專注於非稀釋性資金，推進用於神經退行性和自身免疫疾病的Treg增強生物製品
Dear Fellow Stockholder,
親愛的股東：
Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose bold vision has instilled the "innovation and get-it-done" culture in Coya's DNA. We...
鑑於我最近擔任首席執行官一職，我想分享一下我對Coya和我們未來的看法，並對我們的創始人兼執行主席Dr...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間